Lantern Pharma Inc. (LTRN)
2025-06-30 | ||||
|---|---|---|---|---|
| Other income, net | 206,140 | |||
| Research and development | 3,068,379 | |||
| General and administrative | 1,583,521 | |||
| Total operating expenses | 4,651,900 | |||
| Loss from operations | -4,651,900 | |||
| Interest income | 114,745 | |||
| Net loss | -4,331,015 | |||
| Net loss per share of common shares, basic | -0.4 | |||
| Net loss per share of common shares, diluted | -0.4 | |||
| Weighted-average number of common shares outstanding, basic | 10,784,725 | |||
| Weighted-average number of common shares outstanding, diluted | 10,784,725 | |||